Wilmington, DE -- (SBWIRE) -- 01/15/2014 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Novavax, Inc. (NASDAQ:NVAX) and Amgen Inc. (NASDAQ:AMGN).
Novavax, Inc. (NASDAQ:NVAX) a clinical-stage biopharmaceutical company that focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases is currently down (-2.12%) on 4,542,407 shares traded after Novavax Announced Continuation of RSV Vaccine Partnership With PATH. Novavax, Inc. (NASDAQ:NVAX) is currently down (-6.08%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Novavax, Inc. (NASDAQ:NVAX)
Amgen Inc. (NASDAQ:AMGN) a biotechnology medicines company that engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada is currently up (+0.65%) on 1,635,976 shares traded as Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease. Amgen Inc. (NASDAQ:AMGN) is currently up (+45.84%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Amgen Inc. (NASDAQ:AMGN)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report